Jove
Visualize
Contact Us

Related Concept Videos

Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

238
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
238
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

189
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
189
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

146
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
146
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

227
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
227
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

185
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
185
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

5.1K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial.

Journal of pharmacokinetics and pharmacodynamics·2026
Same author

Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer.

Journal of clinical pharmacology·2025
Same author

Re-Evaluation of Fixed Dosing Versus Body Size-Based Dosing Approaches for Large Molecule Therapeutics in Adults.

Clinical pharmacology and therapeutics·2025
Same author

An Investigation in the Comparability of the Exposure and Recommended Dose of Selected Pfizer Drugs in East Asian Countries: Is Mutual Usage of Clinical Data Among East Asian Countries Feasible?

Journal of clinical pharmacology·2023
Same author

Case-control matching-guided exposure-efficacy relationship for avelumab in patients with urothelial carcinoma.

CPT: pharmacometrics & systems pharmacology·2023
Same author

Optimizing benefit/risk in oncology: Review of post-marketing dose optimization and reflections on the road ahead.

Critical reviews in oncology/hematology·2023
Same journal

The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient.

Clinical pharmacology and therapeutics·2026
Same journal

Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

Clinical pharmacology and therapeutics·2026
Same journal

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

Clinical pharmacology and therapeutics·2026
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 7, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.9K

Optimizing Body Size-Based Dosing Approaches for Antibody-Drug Conjugates.

Andrew B SyBing1, Diane D Wang1

  • 1Pfizer Oncology Early Stage Development, Clinical Pharmacology, San Diego, California, USA.

Clinical Pharmacology and Therapeutics
|December 30, 2025
PubMed
Summary
This summary is machine-generated.

Optimizing antibody-drug conjugate (ADC) dosing is crucial. Using adjusted ideal body weight (AIBW) or body surface area (BSA) with dose capping improves precision, especially when clearance scaling is not ideal.

More Related Videos

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.1K
Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
04:24

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Published on: June 16, 2023

2.2K

Related Experiment Videos

Last Updated: Jan 7, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.9K
Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.1K
Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
04:24

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Published on: June 16, 2023

2.2K

Area of Science:

  • Pharmacology
  • Oncology
  • Drug Development

Background:

  • Antibody-drug conjugate (ADC) dosing precision is challenging due to narrow therapeutic indices and interindividual variability.
  • Body size-based dosing is common but can lead to over- or underexposure if scaling exponents differ from one.
  • Existing ADC dosing strategies may not fully account for allometric scaling characteristics.

Purpose of the Study:

  • To outline a strategy for selecting optimal dosing approaches to enhance ADC dosing precision.
  • To evaluate the performance of different body size metrics (body weight, BSA, IBW, AIBW) for ADC dosing.
  • To assess the effectiveness of dose capping strategies in mitigating exposure variability.

Main Methods:

  • Re-estimated allometric scaling exponent (α) for clearance relative to body weight (BW), body surface area (BSA), ideal body weight (IBW), and adjusted ideal body weight (AIBW).
  • Conducted simulations to evaluate dose capping performance across various α values.
  • Analyzed dosing strategies of 15 approved ADCs.

Main Results:

  • All 15 approved ADCs utilize body size-based dosing, with seven employing dose caps.
  • Adjusted ideal body weight (AIBW) and BSA often showed an allometric scaling exponent (α) closer to 1 than body weight (BW).
  • Dose capping effectively maintained the percentage area under the curve (AUC) difference within a 20% range for extreme body sizes when α was between 0.4 and 0.7.

Conclusions:

  • AIBW and BSA are superior body size metrics for ADC dosing compared to BW or IBW when α is not equal to 1.
  • Dose capping is a valuable strategy to improve ADC dosing precision, particularly when allometric scaling is suboptimal.
  • A decision tree is proposed to guide dosing strategy selection throughout drug development for improved ADC therapeutic outcomes.